In the PALOMA-2 trial, patients with postmenopausal HR+ HER2-negative advanced breast cancer had a better median PFS when palbociclib and letrozole were combined than when letrozole was used alone (Finn et al., 2016). Here, ERBB2 is linked to breast carcinoma.